Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes

Hypoglycemia is de ned non-numerically by the American Diabetes Association as “all episodes of an abnormally low plasma glucose concentration that expose the individual to potential harm” (1). The threshold for clinically signi cant hypoglycemia is 54 mg/dL (3.0 mmol/L), while severe hypoglycemia is de ned as an episode with severe cognitive impairment that requires assistance for recovery (1).